You are here: Introduction > Pharmacological particulars
 
        PreviousNext
 
Tilmovet 100 g/kg Premix:  Pharmacological particulars
 
 
Tilmovet 100 g/kg Premix
Tilmovet 100 g/kg Premix
Pharmacological particulars
Pharmacodynamic properties
Tilmicosin inhibits the bacterial protein synthesis in vitro and in vivo, without affecting the nucleic acid synthesis. It is mostly bacteriostatic. It has a bactericidal effect on Pasteurella spp.
Tilmicosin has a wide spectrum of activity against Gram-positive organisms and some Gram-negative micro-organisms (Pasteurella multocida, Actinobacillus pleuropneumoniae) and Mycoplasma).
Macrolides inhibit protein synthesis by reversibly binding to the 50S ribosomal subunitl. Bacterial growth is inhibited by induction of the separation of peptidyl transfer RNA from the ribosome during the elongation phase.
Ribosomal methylase, encoded by the erm gene, can precipitate resistance to macrolides by alteration of the ribosomal binding site.
The gene that encodes for an efflux mechanism, mef, also brings about a moderate degree of resistance.
Resistance is also brought about by an efflux pump that actively rids the cells of the macrolide. This efflux pump is chromosomally mediated by genes referred to as acrAB genes. Resistance of Pseudomonas species and other Gramnegative bacteria, enterococci and staphylococci may be precipitated by chromosomally controlled alteration of permeability or uptake of the drug.
Pharmacokinetic properties
Absorption: When administered to pigs via the oral route at a dose of 400 ppm in the feed (equivalent to approximately 21.3 mg/kg/day), tilmicosin moves rapidly out of the serum into areas of low pH. The highest concentration in the serum (0.23±0.08 µg/ml) was recorded on day 10 of medication, but concentrations above the limit of quantification (0.10 µg/ml) were not found in 3 out of 20 animals examined. Lung concentrations increased rapidly between days 2 and 4, but no significant changes were obtained following four days of dosing. The maximum concentration in lung tissue (2.59±1.01 µg/ml) was recorded on day 10 of medication.
Distribution: Following oral administration, tilmicosin is distributed throughout the body, but especially high levels are found in the lung and in lung tissue macrophages. It is also distributed in the liver and kidney tissues.
Biotransformation: Several metabolites are formed, the predominant one being identified as T1. However the bulk of the tilmicosin is excreted unchanged.
Elimination: Following oral administration, tilmicosin is excreted mainly via the bile into the faeces, but a small proportion is excreted via the urine
           
 
        PreviousNext
  Date updated: 17 September 2012